Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study

Frontiers in Oncology

Oncology

Tingzhi Yan¹  Daling Dong¹  Chao Wang¹  Qian Yang¹  Gang Xiong¹  Shixin Zhang¹  Bin Jiang¹  Wei Wei¹  Min Chen¹  Liken Zheng²  Weikang Shao² 

[1] Department of Cardiothoracic Surgery, Guiqian International Hospital, Guiyang, China;Genecast Biotechnology Co., Ltd., Wuxi, China;

关键词: molecular residual disease;    liquid biopsy;    non-small cell lung cancer;    adjuvant therapy;    clinicopathological features;    immune markers;   

DOI  :  10.3389/fonc.2023.1275851

 received in 2023-08-10, accepted in 2023-08-15,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Dong, Zhang, Jiang, Wei, Wang, Yang, Yan, Chen, Zheng, Shao and Xiong